These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1750016)

  • 21. Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease.
    Teo E; House H; Lockhart K; Purchuri SN; Pushparajah J; Cripps AW; van Driel ML
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010010. PubMed ID: 25201571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influenza vaccination in patients with asthma: effect on the frequency of upper respiratory tract infections and exacerbations.
    Abadoğlu O; Mungan D; Paşaoglu G; Celík G; Misirligil Z
    J Asthma; 2004; 41(3):279-83. PubMed ID: 15260460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interferon-beta ser as prophylaxis against experimental rhinovirus infection in volunteers.
    Higgins PG; Al-Nakib W; Willman J; Tyrrell DA
    J Interferon Res; 1986 Apr; 6(2):153-9. PubMed ID: 3014018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intranasal interferon-alpha 2 treatment of experimental rhinoviral colds.
    Hayden FG; Gwaltney JM
    J Infect Dis; 1984 Aug; 150(2):174-80. PubMed ID: 6381610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolerance and efficacy of intranasal administration of recombinant beta serine interferon in healthy adults.
    Sperber SJ; Levine PA; Innes DJ; Mills SE; Hayden FG
    J Infect Dis; 1988 Jul; 158(1):166-75. PubMed ID: 2839579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ineffectiveness of recombinant interferon-beta serine nasal drops for prophylaxis of natural colds.
    Sperber SJ; Levine PA; Sorrentino JV; Riker DK; Hayden FG
    J Infect Dis; 1989 Oct; 160(4):700-5. PubMed ID: 2551976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Reduction using an immunomodulator of the level of respiratory infections in chronic bronchitis].
    Rochemaure J; Lehert P; Sauvaget J; Robillard M; Betbeder-Matibet A
    Rev Pneumol Clin; 1988; 44(1):43-7. PubMed ID: 3291072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Ergoferon liquid dosage form--efficacious and safe treatment for childhood acute respiratory infections. Interim outcomes of a multi-center, randomized, double-blind, placebo-controlled clinical trial].
    Geppe NA; Kondiurina EG; Galustian AN; Pak TE; Bal'tserovich NB; Zhiglinskaia OV; Kamaev AV; Lazareva SG; Laléko SL; Mel'nikova IM; Perminova OA; Sabitov AU
    Antibiot Khimioter; 2014; 59(5-6):6-14. PubMed ID: 25552038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ineffectiveness of postexposure prophylaxis of rhinovirus infection with low-dose intranasal alpha 2b interferon in families.
    Monto AS; Schwartz SA; Albrecht JK
    Antimicrob Agents Chemother; 1989 Mar; 33(3):387-90. PubMed ID: 2543280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and tolerance of intranasally applied recombinant leukocyte A interferon in normal volunteers.
    Samo TC; Greenberg SB; Couch RB; Quarles J; Johnson PE; Hook S; Harmon MW
    J Infect Dis; 1983 Sep; 148(3):535-42. PubMed ID: 6619578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of a topical interferon inducer on rhinovirus infections in volunteers.
    Stanley ED; Jackson GG; Dirda VA; Rubenis M
    J Infect Dis; 1976 Jun; 133 Suppl():A121-127. PubMed ID: 180192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of intranasal interferon alpha-2a in respiratory syncytial virus infection in volunteers.
    Higgins PG; Barrow GI; Tyrrell DA; Isaacs D; Gauci CL
    Antiviral Res; 1990 Jul; 14(1):3-10. PubMed ID: 2080867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of respiratory infections on exacerbation of asthma in adult patients. A six-month follow-up.
    Kava T
    Allergy; 1986 Nov; 41(8):556-61. PubMed ID: 3812928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nasopharyngeal Type-I Interferon for Immediately Available Prophylaxis Against Emerging Respiratory Viral Infections.
    Lee AC; Jeong Y; Lee S; Jang H; Zheng A; Kwon S; Repine JE
    Front Immunol; 2021; 12():660298. PubMed ID: 34093548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention from naturally acquired viral respiratory infection by interferon nasal spray.
    Saito H; Takenaka H; Yoshida S; Tsubokawa T; Ogata A; Imanishi F; Imanishi J
    Rhinology; 1985 Dec; 23(4):291-5. PubMed ID: 4081525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tolerance of one-month intranasal interferon.
    Scott GM; Onwubalili JK; Robinson JA; Doré C; Secher DS; Cantell K
    J Med Virol; 1985 Oct; 17(2):99-106. PubMed ID: 2997387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Viral infection in wheezy bronchitis and asthma in children.
    Mitchell I'Inglis H; Inglis H; Simpson H
    Arch Dis Child; 1976 Sep; 51(9):707-11. PubMed ID: 187127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized controlled trial of low-dose recombinant human interferons alpha-2b nasal spray to prevent acute viral respiratory infections in military recruits.
    Gao L; Yu S; Chen Q; Duan Z; Zhou J; Mao C; Yu D; Zhu W; Nie J; Hou Y
    Vaccine; 2010 Jun; 28(28):4445-51. PubMed ID: 20394720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of massive dose of vitamin A given to preschool children with acute diarrhoea on subsequent respiratory and diarrhoeal morbidity.
    Bhandari N; Bhan MK; Sazawal S
    BMJ; 1994 Nov; 309(6966):1404-7. PubMed ID: 7819847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The preventive effect of human interferon-alpha preparation on upper respiratory disease.
    Imanishi J; Karaki T; Sasaki O; Matsuo A; Oishi K; Pak CB; Kishida T; Toda S; Nagata H
    J Interferon Res; 1980; 1(1):169-78. PubMed ID: 6180040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.